Earlier on December 10, Journey Medical Corp published results from a Phase 1 clinical trial, focusing on Emrosi’s impact on microbial flora in healthy adults, in the Journal of Drugs in Dermatology.
Papulopustular eruptions are the most common cutaneous adverse effect of epidermal growth factor receptor (EGFR) inhibitors, typically arising within the first month of therapy. We describe an unusual ...
The neonatal period comprises the first four weeks of life. It is a period of adaptation where the skin often presents several changes: transient lesions, resulting from a physiological response, ...
The medication can be taken with or without food, though ingestion of food along with Emrosi may help reduce the risk of esophageal irritation and ulceration. Emrosi ™ (minocycline hydrochloride ...
State Medicaid formularies demonstrate significant variability in rosacea treatment coverage, with only 10% of states offering unrestricted access to basic therapeutic options, in an analysis of ...
It is important to detect this uncommon pathology in the pediatric population due to its association with immunosuppression, such as malnutrition, HIV, or the presence of hematological malignancy. The ...
Credit: Journey Medical Corporation. The approval was supported by data from 2 randomized, double-blind, active- and placebo-controlled phase 3 trials. Emrosi is expected to be available in the first ...
Please provide your email address to receive an email when new articles are posted on . In a pilot study of 20 patients, 97% reported a reduction in redness and papules and pustules after five ...
Acne is a skin condition characterized by clogged pores. When pores get clogged, it causes red lesions — which you know as pimples — to form on the face or other areas of the body, especially those ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback